Pharmaceuticals company RPG Life Sciences announced Q1FY25 results: Financial Highlights: YoY Revenue from operations: Rs 165.42 crore – up from Rs 147.78 crore YoY PBT: Rs 36.00 crore – up from Rs 29.77 crore The Company maintained an upward trajectory in EBITDA margin, which improved from 23.0% to 25.1% YoY. Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q1FY25, the overall performance of the Company continued to be strong. Revenue and PBT grew by 12% and 21% respectively YoY. Retaining its 5-year upward trajectory, the EBITDA margin crossed the 25% mark (25.1% up from 23.0% last year). Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market - building some of our iconic “Textbook” brands like Naprosyn into megabrands through a comprehensive life cycle management program, shaping one successful product into a multi-product portfolio by leveraging our existing strong customer franchise, building the futuristic portfolio of MABs into a formidable product segment through multibranding strategy, replicating our smart and successful Rheumatology portfolio entry strategy to enter more specialties like Gastro and Derma, and deploying digital and productivity enhancement measures to ensure consistent salesforce productivity gains year-after-year. We are now shaping our International Formulations and API businesses to emerge as second and third growth engines.For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D; laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth and the API business is also showing promising growth. Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted YoY margin expansion trajectory." Result PDF